Jun. 17 at 8:44 PM
$IGC $IGC is building a deep Alzheimer’s pipeline, not betting on a single drug.
✅ IGC-AD1 – Phase 2 candidate showing potential to reduce Alzheimer’s-related agitation while improving cognition.
✅ TGR-63 – Next-generation therapy targeting brain plaque pathways and the underlying disease process.
✅ IGC-1C, IGC-M3 & IGC-LMP – Additional pipeline assets targeting neuroinflammation, oxidative stress, neuronal health, and CNS preservation, giving IGC multiple shots on goal.
✅ AI Platform – Accelerates drug discovery and analyzes clinical data across the entire pipeline.
With multiple Alzheimer’s candidates, AI-driven development, and Phase 2 catalysts already in play,
$IGC has far more value than a typical micro-cap biotech. One major clinical update, partnership, or licensing deal could change everything. 🌙🚀 #IGC #Alzheimers #Biotech #AI #Moonshot
$RXRX $SDGR $ABCL $AXSM
